MHC class I loss in endometrial carcinoma

MHC class I loss by tumor cells decreases tumor neoantigen presentation to the immune system and therefore represents a possible mechanism of immunotherapeutic resistance in cancers that otherwise could be good candidates for checkpoint inhibition (e.g. mismatch repair (MMR)-deficient and PD-L1-positive tumors). In this episode our guest, Dr. Anne Mills discusses her recent Modern Pathology publication on loss of MHC class 1 expression in some endometrial cancers. Study by Friedman et al, MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition. Modern Pathology, 34, 627-636, 2021. https://www.nature.com/articles/s41379-020-00682-w

Hosted on Acast. See acast.com/privacy for more information.

More from ModPath Chat

  1. 17:47Morphologic Feature Guiding Discovery of Driver Genetic Alteration in Rare EntityNov 24, 2022
  2. 25:54Risk Stratification for SLNB in MelanomaNov 10, 2022
  3. 29:59Flat urothelial lesions of the urinary bladder: Who is in who is out?Oct 27, 2022
  4. 17:54Radio-Resistant Prostate Carcinoma: “Cribriform” morphologies and DNA Damage Response and Repair defectsOct 13, 2022
  5. 17:58The Stanford Experience in Implementation of the Molecular Classification of Endometrial carcinomas (EC)Sep 29, 2022
  6. 21:19Expanding the clinico-pathological spectrum of SDH Deficient RCCSep 15, 2022
  7. 22:01High Risk and Selected Benign Breast Lesions on Core Biopsy: Excision Vs Surveillance?Sep 01, 2022
  8. 21:31Are ancillary studies of any utility in risk assessment of Barrett’s esophagus and dysplasia?Aug 18, 2022
  9. 17:55Ki-67 assessment in pancreatic neuroendocrine neoplasms manual vs. digital?Aug 04, 2022
  10. 15:21Heterogeneity of molecular alterations in CRC with peritoneal carcinomatosisJul 21, 2022